Nycomed helps keep Takeda's head above water but deal costs hit profits
This article was originally published in Scrip
Executive Summary
Takeda's first financial figures since the completion of the Nycomed acquisition show that the deal mainly helped Asia's largest pharmaceutical company weather the impact of the strong yen and falling sales of its top products, rather than generating a spectacular surge in top line revenues.